References
- Cetto G L, Franceschi T, Turrina G, et al. Recombinant alpha-interferon and vinblastine in metastatic renal cell carcinoma: Efficacy of low doses. Surg Oncol 1988; 4: 184–90
- Bergerat J-P., Herbrecht R, Dufour P, et al. Combination of recombinant interferon alpha-2A and vinblastine in advanced renal cell cancer. Cancer 1988; 62: 2320–4
- Fosså S D, De Garis S T, Heier M S, et al. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma. Cancer 1986; 57: 1700–4
- Fosså S D, De Garis S T. Further experience with recombinant interferon alfa-2a with vinblastine in metastatic renal cell carcinoma: A progress report. Int J Cancer 1987, Suppl 1: 36–40
- Fosså S D, Raabe N, Moe B. Recombinant interferon-alpha with or without vinblastine in metastatic renal cell carcinoma: Results of a randomized phase-II study. Br J Urol 1989, (In press.)
- Krown S E. Interferon treatment of renal cell carcinoma: Current status and future prospects. Cancer 1987; 59: 647–51
- Muss H B. Interferon therapy of metastatic renal cell cancer. Sem Surg Oncol 1988; 4: 199–203
- Neidhart J, Harris J, Tuttle R. A randomized study of welferon (WFN) with or without vinblastine (VBL) in advanced renal cancer. Proceedings of ASCO 1987; 6: 239
- Sarna G, Figlin R, De Kernion J. Interferon in renal cell carcinoma. The UCLA experience. Cancer 1987; 59: 610–2
- Schornagel J, Verwey J, Bokkel Huinink W, et al. Phase-II study of recombinant interferon alpha-2 (IFN) and vinblastine (V) in advanced renal carcinoma (ARC). Proceedings of ASCO 1987; 6: 106
- Swanson D, Quesada J R. Interferon therapy for metastatic renal cell carcinoma. Sem Surg Oncol 1988; 4: 174–7
- Eker R, Nesland J M, Andersen A, Johannessen J V. Prognostic factors in renal cell carcinoma. Histol Histopath 1986; 1: 255–70
- Schutte B, Reynders M MJ, Bosman F T, Blijham G H. Flow cytometric determination of DNA ploidy level in nuclei isolated from paraffin-embedded tissue. Cytometry 1985; 6: 26–30
- Jacobsen A B, Fosså S D, Lunde S, Melvik J E, Pettersen E O. Comparison of DNA flow cytometry values in bladder carcinoma biopsies obtained from fresh and from paraffin-embedded material. Acta Pathol Scand (A) APMIS 1988; 96: 25–9
- Hedley D W, Friedlander M L, Taylor I W, Rugg C A, Musgrove E A. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 1983; 31: 1333–5
- Vindelév L L, Christensen I J, Nissen N I. A detergent trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983; 3: 323–7
- Fosså S D, Klepp O, Fjaestad K, et al. Inter- and Intra-observer variations in size evaluation of clinically measureable tumor lesions. (Abstract), 626, 13th Int Cancer Congr 1982. Seattle 1982
- Miller A B, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–14
- Muss H B, Costanzi J J, Leavitt R. Recombinant alpha interferon in renal cell carcinoma: A randomized trial of two routes of administration. J Clin Oncol 1987; 5: 286–91
- Ljungberg B, Stenling R, Roos G. DNA content in renal cell carcinoma with reference to tumor heterogeneity. Cancer 1985; 56: 503–8
- Ljungberg B, Stenling R, Roos G. DNA content and prognosis in renal cell carcinoma. A comparison between primary tumors and metastases. Cancer 1986; 57: 2346–50